PTPRC and neoplasm: After 92 h, PBNPs-mediated PTT therapy was able to exert an immunostimulatory effect, boosting the infiltration of CD45+ (9.7% against 4.1% untreated) and CD3+ (6.2% vs. 2.2% untreated) cells to the tumor site.